Angus Liu is a senior writer at Fierce Pharma, currently leading the publication’s oncology coverage, and he also writes about cancer drugs and China-related topics for Fierce Biotech. Angus has reported extensively on oncology, including the rise of checkpoint inhibitors, cell therapies and antibody-drug conjugates. Angus earned his Master’s at Northwestern University’s Medill School of Journalism.